About Us

Royal Power Supports the Construction of Domestic Vaccine Production Bases

Apr 16,2021

The inactivated COVID-19 vaccine jointly developed by the Wuhan Institute of Biological Products of China National Biotec Group (CNBG), Sinopharm, and the Wuhan Institute of Virology of the Chinese Academy of Sciences has been officially launched, becoming the third COVID-19 vaccine granted conditional marketing authorization in China. On the same day, Sinopharm CNBG's Central China Industrial Base was unveiled in Wuhan.

The Jingang Middle Road project of the Sinopharm Jiangxia vaccine production base broke ground in March this year. With the strong support of the Hubei Provincial Party Committee and Government, the Wuhan Municipal Party Committee and Government, and the Jiangxia District Party Committee and Government, and guided by high-standard, high-quality construction requirements, every effort was made to build human vaccine production workshops meeting high-level biosafety standards. After more than 100 days and nights of joint effort alongside the developer and the constructor, the planned goals were achieved, setting yet another “Huoshenshan speed” record in building inactivated COVID-19 vaccine workshops.

 

 

Royal Power continued the service spirit of “rapid response with guaranteed quality and quantity” demonstrated during the pandemic, completing the supply of ventilation equipment for Workshop Buildings No. 12 and No. 18 within ten days. The company exceeded the production tasks assigned to it by China Construction Third Engineering Bureau, contributing its share to the large-scale production of COVID-19 vaccines.

 

The ventilation equipment has been fully loaded and is ready for transport to the vaccine production base.

 

In the battle against the pandemic, Royal Power has always been in action.

 

MESSAGE CONSULTATION

Welcome to leave a message, we will contact you in time!